{"id":"NCT03785964","sponsor":"SpringWorks Therapeutics, Inc.","briefTitle":"Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-17","primaryCompletion":"2022-04-07","completion":"2024-10-17","firstPosted":"2018-12-24","resultsPosted":"2024-06-12","lastUpdate":"2025-01-31"},"enrollment":142,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Desmoid Tumor","Aggressive Fibromatosis"],"interventions":[{"type":"DRUG","name":"Nirogacestat oral tablet","otherNames":["PF-03084014"]},{"type":"DRUG","name":"Placebo Oral Tablet","otherNames":[]}],"arms":[{"label":"Double-Blind Phase - Nirogacestat","type":"EXPERIMENTAL"},{"label":"Double-Blind Phase - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-Label Phase - Nirogacestat","type":"EXPERIMENTAL"}],"summary":"This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.","primaryOutcome":{"measure":"Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.","timeFrame":"On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years","effectByArm":[{"arm":"Double-Blind Phase - Nirogacestat","deltaMin":null,"sd":null},{"arm":"Double-Blind Phase - Placebo","deltaMin":15.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":26},"locations":{"siteCount":52,"countries":["United States","Belgium","Canada","Germany","Italy","Netherlands","United Kingdom"]},"refs":{"pmids":["37347393","36884323"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":69},"commonTop":["Diarrhoea","Nausea","Fatigue","Hypophosphataemia","Headache"]}}